QUAZAR AML-001 Multivariate Analysis: Predictors of Survival Outcomes With Oral Azacitidine (CC-486) Among Patients With AML in Remission After Intensive Chemotherapy

June 4-8, 2021; Online at https://conferences.asco.org/am
Cytogenetic risk and MRD status identified as independent predictors of overall survival and relapse-free survival with oral azacytidine in this multivariate analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 455 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Amer M. Zeidan, MBBS, discusses novel and investigational therapies for treating patients with myelodysplastic syndromes (MDS) in this commentary from Clinical Care Options (CCO)

Amer Zeidan, MBBS Released: November 22, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021

In this commentary from Clinical Care Options (CCO), Dr. Jennifer Woyach discusses patient education and shared decision making in CLL

Jennifer Woyach, MD Released: November 17, 2021

Gain key clinical insights with this slideset from Clinical Care Options (CCO) on how ADCs use for cancer therapy can cause ocular toxicity

Asim V. Farooq, MD Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue